Bruker Acquires Dynamic Biosensors, a Pioneer of Single-Cell Interaction Cytometry Systems for Drug Discovery
Bruker (Nasdaq: BRKR) has acquired Dynamic Biosensors GmbH, a Munich-based pioneer in biosensor development. This acquisition enhances Bruker's biophysical portfolio for analyzing molecular interactions and kinetics in drug discovery and basic research. Dynamic Biosensors' innovative technologies include:
1. The heliXcyto instrument for single-cell Interaction Cytometry (scIC)
2. The heliX+ instrument using switchSENSE® technology with DNA nanolevers
These complement Bruker's Surface Plasmon Resonance (SPR) portfolio, including the new SPR #64 'Triceratops' and Sierra-Pro SPR systems. The combined Bruker Biosensors business now offers a comprehensive range of instruments, workflows, and consumables for studying inter-molecular and molecule-cell interactions in drug discovery. Financial details were not disclosed, but Bruker expects additional revenues greater than $5 million from the acquisition in FY2025, with no material EPS impact.
Bruker (Nasdaq: BRKR) ha acquisito Dynamic Biosensors GmbH, un pioniere nello sviluppo di biosensori con sede a Monaco. Questa acquisizione arricchisce il portafoglio biofisico di Bruker per l'analisi delle interazioni e della cinetica molecolare nella scoperta di farmaci e nella ricerca di base. Le tecnologie innovative di Dynamic Biosensors includono:
1. Lo strumento heliXcyto per la Citometria di Interazione a singola cellula (scIC)
2. Lo strumento heliX+ che utilizza la tecnologia switchSENSE® con nanolever di DNA
Queste tecnologie completano il portafoglio di Risonanza Plasmonica Superficiale (SPR) di Bruker, compresi i nuovi sistemi SPR #64 'Triceratops' e Sierra-Pro SPR. Il business combinato dei biosensori di Bruker offre ora una gamma completa di strumenti, flussi di lavoro e consumabili per studiare le interazioni inter-molecolari e molecola-cellula nella scoperta di farmaci. I dettagli finanziari non sono stati divulgati, ma Bruker prevede ricavi aggiuntivi superiori a 5 milioni di dollari dall'acquisizione nel FY2025, senza impatti materiali sull'EPS.
Bruker (Nasdaq: BRKR) ha adquirido Dynamic Biosensors GmbH, un pionero en el desarrollo de biosensores con sede en Múnich. Esta adquisición mejora el portafolio biofísico de Bruker para analizar interacciones moleculares y cinéticas en el descubrimiento de fármacos y en la investigación básica. Las tecnologías innovadoras de Dynamic Biosensors incluyen:
1. El instrumento heliXcyto para Citometría de Interacción a nivel de célula única (scIC)
2. El instrumento heliX+ que utiliza la tecnología switchSENSE® con nanolevers de ADN
Estas tecnologías complementan el portafolio de Risonancia Plasmonica Superficial (SPR) de Bruker, incluidos los nuevos sistemas SPR #64 'Triceratops' y Sierra-Pro SPR. El negocio combinado de biosensores de Bruker ahora ofrece una gama completa de instrumentos, flujos de trabajo y consumibles para estudiar las interacciones inter-moleculares y molecula-célula en el descubrimiento de fármacos. No se divulgó información financiera, pero Bruker espera ingresos adicionales de más de 5 millones de dólares por la adquisición en el FY2025, sin impacto material en el EPS.
Bruker (Nasdaq: BRKR)가 뮌헨에 본사를 둔 바이오센서 개발의 선두주자인 Dynamic Biosensors GmbH를 인수했습니다. 이번 인수는 Bruker의 분자 상호작용 및 동역학 분석을 위한 생물물리학 포트폴리오를 강화합니다. Dynamic Biosensors의 혁신적인 기술에는 다음이 포함됩니다:
1. 단일 세포 상호작용 세포계측(scIC)을 위한 heliXcyto 기기
2. DNA 나노레버를 사용하는 switchSENSE® 기술이 적용된 heliX+ 기기
이 기술들은 Bruker의 표면 플라즈몬 공명(SPR) 포트폴리오를 보완하며, 새로운 SPR #64 'Triceratops' 및 Sierra-Pro SPR 시스템을 포함합니다. 통합된 Bruker 바이오센서 사업은 이제 약물 발견을 위한 분자-분자 및 분자-세포 상호작용 연구를 위한 포괄적인 도구, 작업 흐름 및 소모품을 제공합니다. 재무 세부 사항은 공개되지 않았지만, Bruker는 FY2025에 인수로 인해 500만 달러 이상의 추가 수익을 예상하고 있으며, EPS에 대한 중대한 영향은 없을 것으로 보입니다.
Bruker (Nasdaq: BRKR) a acquis une entreprise pionnière dans le développement de biosenseurs, Dynamic Biosensors GmbH, basée à Munich. Cette acquisition renforce le portefeuille biophysique de Bruker pour l'analyse des interactions moléculaires et de la cinétique dans la découverte de médicaments et la recherche fondamentale. Les technologies innovantes de Dynamic Biosensors comprennent :
1. L'instrument heliXcyto pour la cytométrie d'interaction à cellule unique (scIC)
2. L'instrument heliX+ utilisant la technologie switchSENSE® avec des nanolevers en ADN
Ceci complète le portefeuille de résonance plasmonique de surface (SPR) de Bruker, y compris les nouveaux systèmes SPR #64 'Triceratops' et Sierra-Pro SPR. Le secteur des biosenseurs combiné de Bruker offre désormais une gamme complète d'instruments, de flux de travail et de consommables pour étudier les interactions intermoléculaires et moléculaire-cellule dans la découverte de médicaments. Les détails financiers n'ont pas été divulgués, mais Bruker s'attend à des revenus supplémentaires de plus de 5 millions de dollars en raison de l'acquisition dans l'exercice 2025, sans impact matériel sur le BPA.
Bruker (Nasdaq: BRKR) hat Dynamic Biosensors GmbH, ein in München ansässiges Pionier in der Entwicklung von Biosensoren, übernommen. Diese Akquisition erweitert das biophysikalische Portfolio von Bruker zur Analyse molekularer Wechselwirkungen und Kinetik in der Wirkstoffentdeckung und Grundlagenforschung. Die innovativen Technologien von Dynamic Biosensors umfassen:
1. Das heliXcyto-Gerät für die Einzelzell-Interaktionszytometrie (scIC)
2. Das heliX+-Gerät, das die switchSENSE®-Technologie mit DNA-Nanolevern verwendet
Diese ergänzen das SPR-Portfolio (Surface Plasmon Resonance) von Bruker, einschließlich der neuen SPR #64 'Triceratops' und Sierra-Pro SPR Systeme. Das kombinierte Geschäftsbereich der Bruker-Biosensoren bietet nun eine umfassende Palette von Instrumenten, Arbeitsabläufen und Verbrauchsmaterialien zur Untersuchung von intermolekularen sowie molekularen Zell-Interaktionen in der Wirkstoffentdeckung. Finanzielle Einzelheiten wurden nicht bekannt gegeben, aber Bruker erwartet für das Geschäftsjahr 2025 zusätzliche Einnahmen von über 5 Millionen Dollar aus der Übernahme, ohne nennenswerte Auswirkungen auf das EPS.
- Acquisition strengthens Bruker's biophysical portfolio for molecular interaction analysis
- Expands Bruker's offerings in drug discovery and basic research
- Combines Dynamic Biosensors' innovative technologies with Bruker's SPR portfolio
- Expected to generate additional revenues > $5 million in FY2025
- None.
Insights
The acquisition of Dynamic Biosensors (DBS) by Bruker is a strategic move that strengthens Bruker's position in the biophysical analysis market, particularly in drug discovery and basic research. This deal expands Bruker's product portfolio with innovative technologies like single-cell Interaction Cytometry (scIC) and switchSENSE®, complementing their existing Surface Plasmon Resonance (SPR) offerings.
While the financial details weren't disclosed, Bruker expects additional revenues of over
For investors, this move signals Bruker's commitment to innovation and market expansion in the high-value pharmaceutical and biotech sectors. The combined portfolio could lead to increased market share and potentially higher profit margins in the long term, although short-term financial impact appears
Bruker's acquisition of Dynamic Biosensors represents a significant advancement in biosensor technology for drug discovery and basic research. The integration of DBS's heliXcyto and heliX+ instruments with Bruker's SPR portfolio creates a comprehensive suite of tools for studying molecular interactions and kinetics.
The heliXcyto's ability to perform single-cell Interaction Cytometry is particularly noteworthy, as it allows for kinetic measurements directly on cells, preserving the native membrane environment. This capability could accelerate drug discovery processes by providing more physiologically relevant data earlier in the research pipeline.
The combined technologies offer a unique value proposition in the market, potentially attracting more pharmaceutical and biotech customers. This could lead to increased adoption of Bruker's biosensor products in drug discovery workflows, solidifying the company's position as a key player in this space and potentially driving long-term growth in the life sciences sector.
Combining Dynamic Biosensors’ Innovative Technologies with Bruker’s High-Performance SPR Portfolio to Establish a Leading Biosensors Business
The heliX biosensor series by Dynamic Biosensors offers comprehensive biophysical characterizations of interactions. (Graphic: Business Wire)
Dynamic Biosensors (DBS) develops and markets innovative technologies for studying complex molecular interactions and kinetics, supporting drug discovery in the pharma and biotech industries, as well as in basic and medical research. The new Dynamic Biosensors heliXcyto instrument performs single-cell Interaction Cytometry (scIC) for kinetic measurements directly on cells, retaining the molecules’ native membrane environment. The heliX+ instrument utilizes switchSENSE® technology, employing DNA nanolevers to functionalize molecules of interest on the chip surface to characterize their binding behavior and kinetics, as well as conformational changes. In combination with Bruker’s high-throughput Surface Plasmon Resonance (SPR) portfolio, which includes the all-new SPR #64 ‘Triceratops’, and the 24- and 32-spot Sierra-Pro SPR systems, the combined Bruker Biosensors business now offers one of the most innovative range of instruments, workflows, and consumables for studying inter-molecular and molecule-cell interactions in the drug discovery pipeline.
Dynamic Biosensors co-founders Dr. Ralf Strasser, now Managing Director, and Professor Ulrich Rant, now Chief Scientific Officer of Bruker Biosensors, said: “The Bruker SPR portfolio represents a great match for our products, and we are excited to work with our new colleagues to further develop a unique and differentiated biosensor business. We are pleased to have found a partner that can support our growth with its global commercial reach and support infrastructure.”
Dr. Meike Hamester, Vice President of Bruker Biosensors, stated: “This strategic acquisition enhances Bruker’s position in the pharma and biotech industries by combining the cutting-edge Dynamic Biosensors instruments and Bruker’s leading high-throughput SPR portfolio, establishing a new technology leader in biosensors with a differentiated offering.”
Wolfgang Kintzel, the former Chairman of the board and Stephan Wehselau, Managing Director of Dynamic Biosensors, added: “The integration of Dynamic Biosensors into Bruker Biosensors aligns with our commitment to delivering best in class products and services. We are thrilled about the unique opportunities this combination will create for our customers worldwide, as well as for our employees and business partners.”
Financial details of the transaction were not disclosed. In FY2025, Bruker Biosensors expects additional revenues greater than
About Bruker Corporation – Leader of the Post-Genomic Era (Nasdaq: BRKR)
Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker’s high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in post-genomic life science molecular and cell biology research, in applied and biopharma applications, in microscopy and nanoanalysis, as well as in industrial and cleantech research, and next-gen semiconductor metrology in support of AI. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit www.bruker.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241002811474/en/
Investor Contact:
Joe Kostka
Associate Director, Investor Relations
Bruker Corporation
T: +1 (978) 313-5800
E: Investor.Relations@bruker.com
Media Contact:
Dr. Meike Hamester
Vice President Bruker Biosensors
Bruker Daltonics
T: +49 421 22050
E: pr@bruker.com
Source: Bruker Corporation
FAQ
What company did Bruker (BRKR) acquire?
How will the acquisition of Dynamic Biosensors impact Bruker's (BRKR) product offerings?
What are the key technologies acquired by Bruker (BRKR) in this acquisition?
What is the expected financial impact of the Dynamic Biosensors acquisition on Bruker (BRKR)?
